Addiction Science & Clinical Practice
February 4, 2026
Maya Appley, Jessica R Gray, Dima Abdulrahim et al.
1 citation
Non-medical ketamine use is becoming increasingly common in the United States (US), but awareness remains limited among US healthcare providers. Here we present the case of a young woman who developed severe ketamine use disorder in the setting of an acute exacerbation of chronic post-traumatic stress disorder (PTSD). She also demonstrated symptoms concerning for two known complications of...
Addiction Science & Clinical Practice
July 21, 2025
Patricia A. Cioe, Garrett S. Stang, Danish Azam et al.
1 citation
People with HIV (PWH) are disproportionately affected by cigarette use, with a 40 - 70% prevalence rate. Although many express a strong interest in quitting, many PWH who smoke experience lower cessation rates with traditional treatments, in part due to their comorbid anxiety and depressive symptoms. Psilocybin, a classic psychedelic referred to as "breakthrough therapy" by the U.S. Food & Drug...
Addiction Science & Clinical Practice
August 29, 2024
Lucinda A Grande, Tom Hutch, Keira Jack et al.
6 citations
Many people with opioid use disorder who stand to benefit from buprenorphine treatment are unwilling to initiate it due to experience with or fear of both spontaneous and buprenorphine-precipitated opioid withdrawal (BPOW). An effective means of minimizing withdrawal symptoms would reduce patient apprehensiveness, lowering the barrier to buprenorphine initiation. Ketamine, approved by the FDA...
Addiction Science & Clinical Practice
September 16, 2022
Vanessa C Somohano, Josh Kaplan, Aurora G Newman et al.
Women with co-occurring posttraumatic stress disorder (PTSD) and substance use disorder (SUD) experience systemic barriers that place them in danger of poorer treatment outcomes. Some mindfulness-based interventions (MBIs) have demonstrated efficacy in reducing PTSD and SUD symptoms. Mindfulness practice is a core component of MBIs, thought to elicit and maintain positive behavioral change;...
Addiction Science & Clinical Practice
September 4, 2022
Lukas Andreas Basedow, Melina Felicitas Wiedmann, Veit Roessner et al.
17 citations
Abstract Background Post-traumatic stress disorder (PTSD) and substance use disorders (SUDs) often co-occur in adolescent patients. Previous research has shown that these patients differ from SUD patients without PTSD in terms of their substance use patterns. In this study, we aimed to test whether substance use in this population is related to an attempt to self-medicate PTSD-related symptoms....
Addiction Science & Clinical Practice
January 19, 2020
Jennifer Rozylo, Keren Mitchell, Mohammadali Nikoo et al.
Abstract Background The requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine/naloxone induction. Case presentation We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in a high-risk patient with a history of failed initiations due, in part, to withdrawal symptoms. Using an assertive outreach model and a...
Addiction Science & Clinical Practice
March 11, 2015
Michael F. Weaver, John A. Hopper, Erik W. Gunderson
135 citations
Recent designer drugs, also known as "legal highs," include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as "bath salts"); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults...
Addiction Science & Clinical Practice
April 11, 2013
Yasuko Fuse-Nagase, Toru Nishikawa
14 citations
A 30-year-old Japanese man with no previous psychiatric history presented to our facility with delusions, which had been ongoing for 2 months. Upon further interview, he confided that he had a past history of recurrent 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT or "Foxy") abuse, as well as a recent history of recurrent ingestion of a legal aromatic liquid used as a recreational drug. After...